SANGAMO THERAPEUTICS, INC (SGMO): Entry into a Material Definitive Agreement
SANGAMO THERAPEUTICS, INC (SGMO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K SANGAMO THERAPEUTICS, INC NASDAQ false 0001001233 0001001233 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of ea
How this was made
The 30-second read
Why it matters
The disclosed transaction frames SGMO’s near-term objective as maximizing stakeholder value via a potential sale of substantially all assets, with Lilly as the minimum bid subject to higher bids and court approval.
Market read
Traders can update probabilities around asset-sale completion, recovery value, and equity/liquidity risk following the Chapter 11 + stalking-horse disclosure.
What to watch
Court approval timing, DIP financing terms (not fully shown here), and which assets/liabilities are assumed can dominate recovery value more than the headline $50M figure.
Background
Sangamo previously faced Nasdaq delisting for minimum bid price and was suspended then moved to OTCQB; this 8-K adds a Chapter 11 filing and a stalking-horse APA.
Ticker impact
Sangamo filed Chapter 11 and entered a $50M stalking-horse asset purchase agreement with Eli Lilly for key technology platforms and IP.
Near-term volatility likely as traders price bankruptcy risk and the probability/timing of court-approved asset sale; upside depends on higher/better bids.
The filing is a primary-source SEC 8-K detailing Chapter 11 petition and a specific stalking-horse APA with consideration and court-approval conditions.
Market effects
Signals continued consolidation pressure in gene-editing/biotech platforms and heightened bankruptcy-to-asset-sale pathways.
US small-cap biotech distress and OTC/Nasdaq trading status can affect liquidity and risk premia for peers.
Limited direct global read-across, but reinforces cross-border pharma interest in distressed platform IP.
Counterpoint
The stalking-horse structure can be a floor that still attracts higher bids; if bidding produces competition, equity could re-rate quickly despite Chapter 11.
Key entities
- companySangamo Therapeutics, Inc.
Chapter 11 debtor-in-possession; entered a stalking-horse asset purchase agreement to sell technology platforms and related IP.
- companyEli Lilly and Company
Stalking-horse bidder/guarantor for the proposed acquisition of specified Sangamo assets for $50M plus assumed liabilities.
- regulator/venueNasdaq Stock Market LLC
Determined delisting due to minimum bid price failure; trading suspension occurred before the Chapter 11 filing.
